NIH TCF Dev and Prod of SARS-CoV-2 Spike tetramers for B Cell Detection

美国国立卫生研究院四聚体核心设施(TCF)分发高质量的试剂，用于检测固有T细胞和经典的CD4和CD8T细胞群。该设施还进行研发，以生产新的试剂和改进现有的四聚体技术。TCF正在生产MHC I类和II类四聚体，用于分离和鉴定SARS-CoV2特异性的CD4和CD8 T细胞，并正在开发用于检测和表征SARS-CoV2特异性B细胞的SARS-CoV-2刺突蛋白四聚体。到目前为止，已向社区分发了56个MHC四聚体，另有35个正在进行中。随着COVID相关研究的增加，订单预计将增加。随着新的T细胞表位和B细胞抗原靶标的确定，将生产和分发更多的试剂。这些四聚体试剂将是评估COVID患者获得性免疫反应或对候选疫苗的反应的宝贵工具。

The NIH Tetramer Core Facility (TCF) distributes high quality reagents for detection of innate T cell and classical CD4 and CD8 T cell populations. This Facility also conducts R&D to produce new reagents and improve existing tetramer technologies. The TCF is producing MHC class I and class II tetramers for isolation and characterization of SARS-CoV2-specific CD4 and CD8 T cells, and is also developing SARS-CoV-2 Spike protein tetramers for detection and characterization of SARS-CoV2 specific B cells. Thus far, 56 MHC tetramers have been distributed to the community, an additional 35 are in-process. Orders are expected to increase as COVID-related research increases. Additional reagents will be produced and distributed as new T cell epitopes and B cell antigen targets are identified. These tetramer reagents will be invaluable tools for evaluation of adaptive immune responses in COVID patients or in response to candidate vaccines.